| Dr Timothy Bruce Jordan, MD | |
|
1530 Us Highway 43, Winfield, AL 35594-5056 | |
| (205) 487-1133 | |
| Not Available |
| Full Name | Dr Timothy Bruce Jordan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 42 Years |
| Location | 1530 Us Highway 43, Winfield, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457309510 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 00010876 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Walker Baptist Medical Center | Jasper, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alteon Health Alabama, Llc | 5698830552 | 31 |
News Archive
"Since the Eisenhower administration, the United States generally has done food aid in a certain way: grow and pack it in this country, ship it across the world on U.S.-flagged ships, then deliver it through American charities, which sell a portion of the food to fund their other programs," columnist Michael Gerson writes in a Washington Post opinion piece.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 8 days ago
| Entity Name | Alteon Health Alabama, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477708857 PECOS PAC ID: 5698830552 Enrollment ID: O20090210000557 |
News Archive
"Since the Eisenhower administration, the United States generally has done food aid in a certain way: grow and pack it in this country, ship it across the world on U.S.-flagged ships, then deliver it through American charities, which sell a portion of the food to fund their other programs," columnist Michael Gerson writes in a Washington Post opinion piece.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy Bruce Jordan, MD 200 Corporate Blvd, Suite 201, Lafayette, LA 70508-3870 Ph: (800) 893-9698 | Dr Timothy Bruce Jordan, MD 1530 Us Highway 43, Winfield, AL 35594-5056 Ph: (205) 487-1133 |
News Archive
"Since the Eisenhower administration, the United States generally has done food aid in a certain way: grow and pack it in this country, ship it across the world on U.S.-flagged ships, then deliver it through American charities, which sell a portion of the food to fund their other programs," columnist Michael Gerson writes in a Washington Post opinion piece.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 8 days ago
Dr. Janet Mccaw Pribble, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1530 Us Highway 43, Winfield, AL 35594 Phone: 205-979-7593 | |
Dr. Farouk Anwarul Raquib, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 125 Bob Lawrence Drive, Winfield, AL 35594 Phone: 205-487-4535 | |
Martin M Hajjar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1530 Us Highway 43, Winfield, AL 35594 Phone: 205-487-7000 Fax: 205-487-7666 | |
Derek Sloane Cannon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1530 Us Highway 43, Winfield, AL 35594 Phone: 205-487-7000 Fax: 877-915-6502 | |
Dr. Douglas M Martin, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1530 Us Highway 43, Winfield, AL 35594 Phone: 205-487-7000 Fax: 205-487-7179 |